Cargando…

Integrated analysis reveals prognostic value of HLA-I LOH in triple-negative breast cancer

BACKGROUND: Triple-negative breast cancers (TNBCs), especially those non-immune-inflamed tumors, have a poor prognosis and limited therapies. Human leukocyte antigen (HLA)-I not only contributes to antitumor immune response and the phenotype of the tumor microenvironment, but also is a negative pred...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Yi-Fan, Xiao, Yi, Jin, Xi, Di, Gen-Hong, Jiang, Yi-Zhou, Shao, Zhi-Ming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Immunotherapy Biomarkers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8496394/ https://www.ncbi.nlm.nih.gov/pubmed/34615706 http://dx.doi.org/10.1136/jitc-2021-003371

Ejemplares similares

Prognostic value of HLA-I homozygosity in patients with non-small cell lung cancer treated with single agent immunotherapy
por: Abed, Afaf, et al.
Publicado: (2020)

Modification of PLAC8 by UFM1 affects tumorous proliferation and immune response by impacting PD-L1 levels in triple-negative breast cancer
por: Mao, Misha, et al.
Publicado: (2022)

Prognostic value of novel immune-related genomic biomarkers identified in head and neck squamous cell carcinoma
por: Yao, Yao, et al.
Publicado: (2020)

Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers
por: Rozenblit, Mariya, et al.
Publicado: (2020)

Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancer
por: Chun, Brie, et al.
Publicado: (2022)

Evaluation of tumor antigen-specific antibody responses in patients with metastatic triple negative breast cancer treated with cyclophosphamide and pembrolizumab
por: Routh, Eric D, et al.
Publicado: (2023)

Label-free metabolic imaging for sensitive and robust monitoring of anti-CD47 immunotherapy response in triple-negative breast cancer
por: Yang, Minfeng, et al.
Publicado: (2022)

Prognostic value of immune score in nasopharyngeal carcinoma using digital pathology
por: Wang, Ya-Qin, et al.
Publicado: (2020)

Analytical validation of the Immunoscore and its associated prognostic value in patients with colon cancer
por: Marliot, Florence, et al.
Publicado: (2020)

Soluble HLA peptidome of pleural effusions is a valuable source for tumor antigens
por: Khazan-Kost, Sofia, et al.
Publicado: (2022)

Prognostic value of von Willebrand factor levels in patients with metastatic melanoma treated by immune checkpoint inhibitors
por: Stadler, Julia-Christina, et al.
Publicado: (2023)

Synergic prognostic value of 3D CT scan subcutaneous fat and muscle masses for immunotherapy-treated cancer
por: Decazes, Pierre, et al.
Publicado: (2023)

Assessing treatment outcomes of chemoimmunotherapy in extensive-stage small cell lung cancer: an integrated clinical and radiomics approach
por: Zhao, Jie, et al.
Publicado: (2023)

FOXP3-based immune risk model for recurrence prediction in small-cell lung cancer at stages I–III
por: Jiang, Minlin, et al.
Publicado: (2021)

Dominant neoantigen verification in hepatocellular carcinoma by a single-plasmid system coexpressing patient HLA and antigen
por: Chen, Pu, et al.
Publicado: (2023)

Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma
por: Yang, Lei, et al.
Publicado: (2022)

Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade
por: Correale, Pierpaolo, et al.
Publicado: (2020)

Intratumoral PPT1-positive macrophages determine immunosuppressive contexture and immunotherapy response in hepatocellular carcinoma
por: Weng, Jialei, et al.
Publicado: (2023)

Predictive value of integrated (18)F-FDG PET/MRI in the early response to nivolumab in patients with previously treated non-small cell lung cancer
por: Umeda, Yukihiro, et al.
Publicado: (2020)

Transcriptional analysis of multiple ovarian cancer cohorts reveals prognostic and immunomodulatory consequences of ERV expression
por: Natoli, Marina, et al.
Publicado: (2021)

CTLA4 promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma
por: Klümper, Niklas, et al.
Publicado: (2021)

Heterogeneity of tumor immune microenvironment of EGFR/ALK-positive tumors versus EGFR/ALK-negative tumors in resected brain metastases from lung adenocarcinoma
por: Xiao, Gang, et al.
Publicado: (2023)

Paired primary and metastatic lesions of patients with ipilimumab-treated melanoma: high variation in lymphocyte infiltration and HLA-ABC expression whereas tumor mutational load is similar and correlates with clinical outcome
por: Gorris, Mark A J, et al.
Publicado: (2022)

HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma
por: Zhou, Qiang-Hua, et al.
Publicado: (2020)

Galectin-9-based immune risk score model helps to predict relapse in stage I–III small cell lung cancer
por: Chen, Peixin, et al.
Publicado: (2020)

Immune landscape and subtypes in primary resectable oral squamous cell carcinoma: prognostic significance and predictive of therapeutic response
por: Diao, Pengfei, et al.
Publicado: (2021)

First-in-human DR5 PET reveals insufficient DR5 expression in patients with gastrointestinal cancer
por: Wang, Shujing, et al.
Publicado: (2021)

High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC
por: Frigola, Joan, et al.
Publicado: (2022)

Single-cell immune signature for detecting early-stage HCC and early assessing anti-PD-1 immunotherapy efficacy
por: Shi, Jiawei, et al.
Publicado: (2022)

Oncogenic states dictate the prognostic and predictive connotations of intratumoral immune response
por: Roelands, Jessica, et al.
Publicado: (2020)

Prognostic significance of myeloid immune cells and their spatial distribution in the colorectal cancer microenvironment
por: Väyrynen, Juha P, et al.
Publicado: (2021)

Clinicopathological and predictive value of MAIT cells in non-small cell lung cancer for immunotherapy
por: Shi, Lin, et al.
Publicado: (2023)

Immunologic constant of rejection signature is prognostic in soft-tissue sarcoma and refines the CINSARC signature
por: Bertucci, Francois, et al.
Publicado: (2022)

CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer
por: Peng, Qi-Hua, et al.
Publicado: (2021)

Multimodule characterization of immune subgroups in intrahepatic cholangiocarcinoma reveals distinct therapeutic vulnerabilities
por: Lin, Jian, et al.
Publicado: (2022)

New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors
por: Bamias, Aristotelis, et al.
Publicado: (2023)

eEF2K promotes PD-L1 stabilization through inactivating GSK3β in melanoma
por: Chen, Xisha, et al.
Publicado: (2022)

On-treatment immune prognostic score for patients with relapsed and/or metastatic head and neck squamous cell carcinoma treated with immunotherapy
por: Nenclares, Pablo, et al.
Publicado: (2021)

Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors
por: Brown, Jacqueline T, et al.
Publicado: (2021)

TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor
por: de Kouchkovsky, Ivan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bfu05dhlgvt24juqu164s4a9un